Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
55.40% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AUPH · Sep 30, 2026
Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration
State dimensions
Filing0001600620-26-000075General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
13.93% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
52.24% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
90.08% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
42.25% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
19.85% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
7.32% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesSelf-history eligible
Mar 31, 20210/6 normalizedLevel 3Jun 30, 20210/6 normalizedLevel 3Sep 30, 20210/6 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20225/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Sep 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 63.17%
- Current
- 55.40%
- Delta
- -7.77%
- Previous
- 18.87%
- Current
- 13.93%
- Delta
- -4.95%
- Previous
- 54.25%
- Current
- 52.24%
- Delta
- -2.01%
- Previous
- 92.12%
- Current
- 90.08%
- Delta
- -2.05%
- Previous
- 55.68%
- Current
- 42.25%
- Delta
- -13.43%
- Previous
- 15.68%
- Current
- 19.85%
- Delta
- 4.17%
- Previous
- 3.41%
- Current
- 7.32%
- Delta
- 3.91%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
- Similarity
- 91%
- Compared
- 7 dimensions
- Coverage
- 100%
- Similarity
- 87%
- Compared
- 7 dimensions
- Coverage
- 100%
- Similarity
- 79%
- Compared
- 6 dimensions
- Coverage
- 86%
- Similarity
- 79%
- Compared
- 7 dimensions
- Coverage
- 100%
- Similarity
- 78%
- Compared
- 7 dimensions
- Coverage
- 100%
Research Graph
Related governed research
Analogous To · AUPH state analogue 1 →Analogous To · AUPH state analogue 5 →Analogous To · AUPH state analogue 4 →Analogous To · AUPH state analogue 3 →Compared To · Pharmaceutical Preparations peers →Analogous To · AUPH state analogue 2 →Derived From · AUPH Company Quality Vector →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH CASH_GENERATION_DECREASED →Transitioned To · AUPH GROWTH_DECREASED →Transitioned To · AUPH INVENTORY_PRESSURE_DECREASED →Transitioned To · AUPH MARGIN_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.